Indivior PLC (NASDAQ:INDV) Sees Significant Growth in Short Interest

Indivior PLC (NASDAQ:INDV) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,220,000 shares, a growth of 9.9% from the December 15th total of 1,110,000 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is presently 1.0 days.

Indivior Stock Performance

Shares of NASDAQ INDV traded down $0.01 during trading hours on Friday, reaching $11.65. 1,060,388 shares of the stock were exchanged, compared to its average volume of 974,047. Indivior has a 52 week low of $7.33 and a 52 week high of $23.22. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -291.18 and a beta of 0.74. The stock’s fifty day simple moving average is $11.46 and its 200 day simple moving average is $11.07.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $307.00 million during the quarter, compared to analysts’ expectations of $302.25 million. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. Research analysts predict that Indivior will post 1.62 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $16.00 price objective (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum dropped their target price on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th.

Institutional Investors Weigh In On Indivior

Hedge funds have recently added to or reduced their stakes in the business. Stifel Financial Corp acquired a new stake in Indivior in the third quarter valued at approximately $100,000. Melqart Asset Management UK Ltd bought a new position in shares of Indivior during the third quarter valued at about $132,000. Jane Street Group LLC bought a new position in shares of Indivior in the third quarter valued at approximately $180,000. Bank of New York Mellon Corp purchased a new stake in shares of Indivior during the 2nd quarter valued at $188,000. Finally, XTX Topco Ltd purchased a new stake in Indivior during the second quarter worth about $249,000. 60.33% of the stock is currently owned by institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.